Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

(2018) John Mascarenhas et al.   JAMA Oncology

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

(2017) Ruben A Mesa et al.   Lancet Haematology

Does ruxolitinib prolong the survival of patients with myelofibrosis?

(2016) Francisco Cervantes et al.   BLOOD

The future of JAK inhibition in myelofibrosis and beyond

(2014) John O. Mascarenhas et al.   BLOOD REVIEWS

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA